Comparative Pharmacology
Head-to-head clinical analysis: BETHKIS versus GENOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETHKIS versus GENOPTIC.
BETHKIS vs GENOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
4 IU/kg (1 mg/kg) intramuscularly or subcutaneously once weekly for 4 weeks, then a maintenance dose of 2 IU/kg (0.5 mg/kg) once weekly.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
None Documented
None Documented
Terminal elimination half-life 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Primarily renal excretion of unchanged drug via glomerular filtration; ~90% of absorbed dose excreted in urine within 24 hours; biliary/fecal elimination <5%.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic